Data from pre-clinical studies using the PAT-DX1 and PAT-DX3 of Patrys Ltd (ASX:PAB) in animal models of high-grade glioma will be presented at a key brain cancer conference in the US this weekend.
The work of Patrys will be highlighted during a poster discussion at the American Assocation for Cancer Research (AACR) Special Conference on Brain Cancer in Minneapolis, Minnesota, on Saturday, October 21.
Poster presentation
A poster titled 'A novel lupus-associated antibody that inhibits the growth of aggressive high-grade glioma orthotopic xenografts and enhances radiotherapy via a unique mechanism' will be presented by Professor Terrance Johns from the Telethon Kids Cancer Centre in Perth.
It will describe research conducted in his laboratory confirming the single agent activity of PAT-DX1 and PAT-DX3 in animal models of high-grade glioma, as well as the significant survival benefits from combining PAT-DX1 with a therapeutic dose of radiation that Patrys announced on August 10, 2022.
“Enhances radiotherapy”
Professor Johns said: “I am excited to present our findings with PAT-DX1 and PAT-DX3 at the AACR Special Conference in Cancer Research: Brain Cancer.
"Through my partnership with Patrys we have demonstrated both antibodies reach and inhibit the growth of intracranial brain cancers in rodent models.
"Significantly, we have shown that PAT-DX1 dramatically enhances the activity of radiotherapy, which is the standard of care for many forms of brain cancer.”
About the conference
The AACR Special Conference on Brain Cancer is one of the world’s leading meetings for profiling new developments in brain cancer research and treatment.
Patrys said the AACR conference presented a rare opportunity to communicate the potential of its’ deoxymabs in advancing brain cancer treatments to a worldwide audience of clinical experts and researchers and demonstrate how they open up new approaches for the treatment of cancers of the brain.
“This global exposure, bolstered by our collaboration with top-tier partners like Professor Johns and his team, strengthens Patrys' efforts in assembling a robust evidence portfolio, paving the way for our first in-human clinical trial in 2024.”
About high-grade gliomas
High-grade gliomas are tumours of the glial cells, cells found in the brain and spinal cord.
They are called 'high-grade' because the tumours are fast-growing creating pressure in nearby normal brain tissue, which makes them hard to treat.
The tumours occur in children of all ages, from infants to adults.